Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the final patient has completed treatment in the LuPIN study.
The study is examining the combination of the company's Veyonda and 177LuPSMA-617 in 56 late-stage prostate cancer patients at St Vincent’s Hospital in Sydney.
LuPIN is a dose-response study involving 400, 800 and 1200 mg Veyonda dosages with a constant 177LuPSMA-617 dosage.
Interim data on the first 32 patients (400 and 800 mg) has been presented at medical conferences and published in a peer-reviewed journal (see announcements 12 Nov 2019 and 14 Feb, 3 March, 1 Jun and 11 Aug 2020).
The company said these two lower dosages (400 and 800 mg) have produced encouraging data with tumour response outcomes, most notably a median overall survival of 17.1 months in men with limited survival expectations.
It said data from the final 24 patients who received the highest (1200 mg) dosage is yet to be reported. The last patient has just completed study treatment.
The next set of interim data is planned to be presented and published in the first quarter of 2021, said the company.